# A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

> **NCT07323173** · PHASE1 · RECRUITING · sponsor: **Nanjing Leads Biolabs Co.,Ltd** · enrollment: 112 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** LBL-047 for Injection
- **DRUG:** LBL-047 placebo for injection

## Key facts

- **NCT ID:** NCT07323173
- **Lead sponsor:** Nanjing Leads Biolabs Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2027-12-16
- **Final completion:** 2027-12-16
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07323173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07323173, "A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07323173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*